---
title: Evaluating the impact of CRBN mutations on response to immunomodulatory drugs
  and novel CRBN-binding agents in myeloma
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39841463/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250123170657&v=2.18.0.post9+e462414
source: Blood
description: Immunomodulatory drug (IMiD) resistance is a key clinical challenge in
  myeloma treatment. Previous data suggests almost one third of myeloma patients acquire
  mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory.
  Some events, including stop codons/frameshift mutations and copy loss, having clearly
  explicable effects on cereblon function. Missense mutations have also been reported
  throughout the length of cereblon but their functional impact has not ...
disable_comments: true
---
Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function. Missense mutations have also been reported throughout the length of cereblon but their functional impact has not ...